Health Canada Approves Optimi Health Precursor License to Formulate MDMA and Encapsulate Various Dosages
Optimi Health recently received a Precursor License to import the precursor of MDMA and encapsulate the drug into specific dosages.
In a recent press release, Optimi Health, “a Health Canada licensed drug researcher and formulator specializing in controlled psychedelic substances such as natural psilocybin and MDMA,” (1) announced that they received a Precursor License for 3,4-Methylenedioxyphenyl-2-propanone (MDP2P) from Health Canada. This chemical compound is the predecessor to 3,4-Methylenedioxymethamphetamine (MDMA) (1).
Optimi Health gained their Precursor License back in December 2023 (1) through Section 16 of the Precursor Control Regulations. This access provides the drug researcher to “import MDP2P for the purpose of formulating and verifying MDMA drug candidates” at the their research and analytical facility located in Princeton, British Columbia, Canada (1). Health Canada had also toured the establishment recently.
“Securing our precursor licence represents a pivotal advantage for Optimi, offering a compelling edge in producing MDMA at significantly reduced costs,” Jacob Safarik, Optimi Chief Financial Officer, commented (1). “This strategic move aligns with our intent to address market demand for GMP MDMA in 2024, especially amid the heightened anticipation surrounding the recent New Drug Application (NDA) submission by the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS PBC) to the U.S Food and Drug Administration (FDA).”
The Chief Financial Officer also mentioned a recent update stemming from the American Medical Association (1), “With the AMA’s current procedural terminology ("CPT") III codes for psychedelic-assisted therapies now officially in effect, this underscores the goal of obtaining our precursor license. With potential FDA approval, physicians and other qualified healthcare providers seeking coverage and reimbursement for delivering psychedelic-assisted therapy will now have a reliable partner who can formulate and encapsulate the most cost-effective, high-quality, and accessible MDMA solutions in the market.”
After obtaining the Precursor License, Optimi Health was able to encapsulate MDMA into two dosage formats, 40mg and 60mg (1). “This milestone is more than formulation. It symbolizes our dedication to achieving scientific uniqueness in alliance with industry pioneers such as the MAPS PBC who are paving the road ahead,” Dr. Preston A. Chase said (1). “Our innovation journey is grounded in advancing the safety and validity of our MDMA drug candidate, and I am happy to say that we’re just hitting our stride in becoming the premier provider of fully verified, encapsulated MDMA in 2024 and beyond.”
In one of the last developments Optimi Health disclosed in their press release (1) is that they are working on being granted a Certificate of Analysis (COA) from a third-party laboratory which will help provide their clients with further assurance.
Reference
- Optimi Health Corp. Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats https://www.globenewswire.com/news-release/2024/01/03/2803195/0/en/Optimi-Health-Granted-Precursor-Licence-To-Formulate-MDMA-And-Completes-Encapsulation-Of-40mg-And-60mg-Dosage-Formats.html (accessed Jan 3, 2024).
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
